TCGA-58-8388-01A-11R-2326-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.410
- MITOTIC_SPINDLE+0.380
- G2M_CHECKPOINT+0.340
- HEDGEHOG_SIGNALING+0.330
- E2F_TARGETS+0.230
- NOTCH_SIGNALING+0.210
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.190
- UV_RESPONSE_DN+0.110
- TGF_BETA_SIGNALING+0.100
- ANGIOGENESIS+0.070
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.590
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- MTORC1_SIGNALING-0.440
- FATTY_ACID_METABOLISM-0.410
- CHOLESTEROL_HOMEOSTASIS-0.390
- XENOBIOTIC_METABOLISM-0.390
- ANDROGEN_RESPONSE-0.370
- ADIPOGENESIS-0.330
- APOPTOSIS-0.320
- PEROXISOME-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 824433bf-151c-46ea-9ea7-f53813f66a97 | — | — | 0.888 |
| 2 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.881 |
| 3 | MNG790 | — | — | 0.851 |
| 4 | a83e78c0-8b1b-4576-aace-4bee1dee5046 | — | — | 0.849 |
| 5 | SRR6013547 | — | cohortMD1 | 0.848 |
| 6 | 20120197.TNBC | — | D | 0.843 |
| 7 | SRR1313145 | — | D | 0.834 |
| 8 | 0918cbd5-edd0-41c8-8b67-677f35ad4611 | — | — | 0.834 |
| 9 | TCGA-90-A4ED-01A-31R-A24Z-07 | — | cohortMD1 | 0.830 |
| 10 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |